-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Histiocytic Disorders: Novel Insights into Biology and Implications for Therapy (Langerhans and Erdheim-Chester)

Program: Education Program
Session: Anxiety Provoking Hematology Consults, Second Edition
Hematology Disease Topics & Pathways:
Biological, Diseases, Therapies, Combinations, Myeloid Malignancies
Saturday, December 5, 2020, 11:55 AM-12:00 PM

Kenneth L. McClain, MD, PhD

Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX

Disclosures: McClain: SOBI: Membership on an entity's Board of Directors or advisory committees.

OffLabel Disclosure: Use of MAP2K inhibitors for Langerhans cell histiocytosis

Previous Presentation | Next Presentation >>